Press Release U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma 7 hours ago
Press Release Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results Aug 6